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ABSTRACT
The purpose of the study was to conduct two meta-analytic reviews examining cognitive
functioning and schizophrenia. The first review examined the literature comparing the
cognitive functioning of schizophrenic patients to healthy controls. A second review
examined the cognitive functioning within schizophrenic patients, examining the
differences between individuals with primarily positive symptomatology and those with
primarily negative symptomatology. The first meta-analysis included 19 studies which
assessed 861 schizophrenic patients and 858 healthy volunteers overall. The second metaanalysis included 10 studies comparing the cognitive functioning of 1,263 schizophrenics
across positive and negative symptoms. Results of the first review indicated that healthy
controls performed better than schizophrenics in all areas of neuropsychological
functioning. Results of the second meta-analysis indicated that schizophrenics with
primarily positive symptomatology performed better in all areas of functioning, with the
exception of attention.
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CHAPTER I
A META-ANALYTIC REVIEW OF COGNITIVE FUNCTIONING IN NEGATIVE
AND POSITIVE SYMPTOMS OF SCHIZOPHRENIA
Epidemiology and Diagnostic Criteria of Schizophrenia
Researchers have found that 1.1% of the world-wide population are diagnosed
with schizophrenia (Schizophrenia and Related Disorders Alliance of America, 2018) and
according to the World Health Organization, this number is about 21 million people,
worldwide (World Health Organization, 2018). The literature on etiology is continually
expanding and suggests a multifactorial etiology including genetic and environmental
factors. Schizophrenia is categorized under psychotic disorders, and clinical symptoms
include by delusions, hallucinations, disorganized thinking, disorganized motor behavior,
blunted affect, avolition, anhedonia, alogia, and asociality (American Psychiatric
Association, 2013). Individuals diagnosed with schizophrenia will vary widely in these
symptoms due to its heterogeneity (American Psychological Association, 2013).
Cognitive symptoms are also present in schizophrenia and include changes in memory,
attention, and executive functioning (National Institute of Mental Health, 2016).
Cognitive impairment is central in predicting functional outcome of those diagnosed with
schizophrenia and predicting the prognosis one might face (Bowie & Harvey, 2006).
Declining cognitive abilities can overlap and impact many areas of an individual’s life,
such as vocational, social, and daily living skills, leading to increased disability reliance.
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Schizophrenia has unfolded over the years as a neuropsychological disease, responding to
neuroleptic medications and neuropharmacological research (Liberman & Corrigan,
1992).
Genetic Factors and Biology
According to the National Alliance of Mental Illness, schizophrenia is linked to a
genetic predisposition (National Alliance of Mental Illness, 1998). Multiple studies have
found a high degree of heritability of schizophrenia (Gareeva & Khusnutdinova, 2018).
Genetic research is emerging as a promising contribution to understanding schizophrenia
development. Bassett, Chow, Weksburg, & Brzustowicz (2002) discussed the
identification of 22q deletion syndrome (22qDS), multiple susceptibility genes, and new
mutations. The mutation 22qDS is characterized by microdeletions in the “Q” arm of
chromosome 2, which increases the risk for schizophrenia (Basset et al., 2002) as well as
other neurodevelopmental brain disorders (Larsen, Dzafic, Siebner, & Garrido, 2018).
The 22qDS mutation is characterized by abnormalities in sensory processing and
cognition (Larsen et al., 2018). Studies that have examined this mutation have found that
those individuals with 22qDS are at risk to develop psychosis, and over 25% will develop
schizophrenia (Bassett et al., 2002; Murphy, Jones, & Owen, 1999). According to the
Encyclopedia of the Human Genome, (Murphy, 2003) 22q11, better known as
Velocardiofacial Syndrome, is the most significant risk factor for the development of
schizophrenia. Statistically, the rate of 22q11.2 microdeletion is estimated at a rate of 1
per 4,000 live births making it the most common microdeletion syndrome (Bassett et al.,
2002).
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There is also increased evidence for another gene, DISC1, disrupted in
schizophrenia 1 gene, associated with schizophrenia in Scottish and Finnish population
(Ekelund et al., 2001; Millar et al., 2000; Prus, 2018). This gene codes for the DISC1
protein, which mediates signaling events occurring within neurons and is involved in the
development of neurons (Hayashi-Takagi et al., 2010; Hodgkinson et al., 2004; Mao et
al., 2009; Prus, 2018). Hodgkinson et al. (2004) propose that haploinsufficiency is a
possible precursor to DISC1 disruption, and Hayashi-Takagi et al. (2010) further posit
disturbances in glutamatergic neurotransmission through DISC1 disruption and potential
changes to dendritic spines.
Not only can genetic mutations affect risk of schizophrenia but alterations in
epigenetic regulation of normal genes through DNA methylation have been reported in
the brains of patients with psychosis (Chen et al., 2014). Methylation is the additive of a
methyl group. DNA methylation reduces gene expression, and demethylation increases
gene expression. These processes are being explored with regard to the etiology of
schizophrenia (Grayson & Guidotti, 2013). Jaffe et al. (2016) examined changes in DNA
methylation levels in relation to genetic sequence and developmental stage associated
with clinical risk for schizophrenia (Jaffe et al., 2016).
Recent evidence also suggests that the cerebellum plays an important role in
schizophrenia and other psychotic disorders, leading researchers to search the cerebellum
for psychosis (Chen et al., 2014). To date, cerebellar function is associated with
depression and mania (Konarski, McIntyre, Grupp, & Kennedy, 2005). Konarski et al.
(2005) presented evidence that those with schizophrenia have modified cortico-cerebellar
connectivity. Andreasen et al. (1996) and Wiser et al. (1998) reported the role of the
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cortico-cerebellar connectivity in monitoring and coordinating the fluid execution of
mental activity geared toward normal cognitive functioning. Disruption of these
pathways could lead to the disordered cognition and clinical symptoms of schizophrenia.
The prefrontal cortex (PFC) has played a more famously recognized role of
schizophrenia symptomatology. The PFC is responsible for language, speech, and
executive functions, which are disrupted in schizophrenia (Andreasen, Paradiso, &
O’Leary, 1998). The PFC also shows extensive interconnections with other cortical and
subcortical regions that are affected by schizophrenia (Andreasen, Paradiso, O’Leary,
1998). Other related areas being researched include the thalamus and hippocampus
(Andreasen, Paradiso, & O’Leary, 1998; Pakkenberg, 1990; Stevens, 1982; Vukadinovic,
2014).
Historically, the first etiologic hypothesis for schizophrenia was the dopamine
hypothesis (Prus, 2018). The dopamine hypothesis explains positive symptoms of
schizophrenia as due to increased dopamine release in the mesolimbic system (Meltzer &
Stahl, 1976; Prus, 2018) This hypothesis remains influential in schizophrenia (Howes &
Kapur, 2009; Prus, 2018). Glutamate is another neurotransmitter that has been found to
play a role in the etiology of schizophrenia, with decreased in glutamate release
throughout the cerebral cortex and limbic system of schizophrenia patients (Paz, Tardito,
Atzori, & Tseng, 2008; Prus, 2018; 2008; Sesack, Carr, Omelchecnko, 2006).
Overall, the neurological understanding of the development of schizophrenia is
complex and intricate, including genetic abnormalities, reduced volume within brain
structures, and unusual or atypical connectivity among brain structures (Lewis &
Lieberman, 2000; Prus, 2018, Ross, Margolis, Reading, Pletnikov, & Coyle, 2006).
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Environmental Factors
Environmental risk factors for schizophrenia include elements of both the prenatal
uterine environment and the external environment in which the individual continues to
develop following birth. Vulnerability to schizophrenia can be increased by disruptions in
brain development as a result of prenatal and perinatal complications, maternal substance
misuse, and early life stressors (Howes et al., 2003). The uterine environment is vital to
development and decreased folate levels during pregnancy have been linked to
schizophrenia risk (Opler et al., 2013). Many schizophrenia studies have reported a
linkage with season of birth and schizophrenia (Demler, 2011; Torrey, Rawlings, Ennis,
Merrill, & Flores, 1996), and other studies have explored the interaction of folate levels
and birth season (Muntjewerff, Ophoff, Buizer-Voskamp, Strengman, & Heijer, 2011).
Late winter and early spring births are correlated to increased risk of schizophrenia.
Interestingly, summer births are associated with predominantly negative symptoms of
schizophrenia (American Psychological Association, 2013).
More recently, research reports that paternal age may be a link to schizophrenic
predisposition, and this may be increasingly important as couples are starting to build
their families later in life (American Psychological Association, 2013; Bassett, Chow,
Weksberg, & Brzustowicz, 2002). Studies suggest that paternal ages 40 years old and
above increase the risk for schizophrenia in their offspring (Byrne, Agerbo, Ewald,
Eaton, & Mortensen, 2003; Malaspina, Harlap, & Fenning, 2001).
Socioeconomic factors have been considered due to exposure to pollution, stress,
and increased risk behaviors (Opler, Charap, Greig, Stein, Polito, & Malaspina, 2013).
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By impacting neural and cognitive development, socioeconomic factors can increase an
individual’s susceptibility to psychosis (Opler et al., 2013; Spauwen, Krabbendam, Lieb,
Wittchen, & Van Os, 2004).
Positive and Negative Symptomatology
As early as 1861, Russell Reynolds introduced the distinction between positive
and negative neurological symptoms as excess or deficit of vital properties (Pearce,
2004). Reynolds, along with Hughlings Jackson, can be credited with the application of
positive and negative symptoms to psychiatry (Pearce, 2004). By 1970, the terms
negative and positive symptoms emerged as diagnostic terminology in schizophrenia
(Jablensky, 2010). To date, according to The National Institute of Mental Health (2016),
schizophrenic symptoms can be classified into three categories: positive, negative, and
cognitive. Schizophrenia symptoms make reliable sub-phenotypes due to the genetic
basis for differences in their clinical presentations (Arnedo et al., 2015). These subphenotypes also have characteristic heritability of symptoms (Kendler et al., 1993). The
availability of valid and reliable measures of negative and positive symptoms such as
Positive and Negative Syndrome Scale (PANSS), Scale for Assessment of Positive
Symptoms (SAPS), and Scale for Assessment of Negative Symptoms (SANS) (Kay,
Flazbein, & Opler, 1987) contribute to the conversation of sub-phenotypes.
Epidemiology and diagnosis. Positive symptoms in schizophrenia include
symptoms in excess of normal and healthy functioning. Positive symptoms include
hallucinations, delusions, thought disorder, and movement disorder (National Institute of
Mental Health, 2016). Negative symptoms in schizophrenia include absences or
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disruption to normal emotions and behaviors, such as a flat affect, anhedonia, alogia, and
avolition (National Institute of Mental Health, 2016).
Fenton and McGlashan (1991) found that individuals with primarily negative
symptoms experience a more severe and progressive course leading to permanent
disability, whereas individuals with fewer negative symptoms experience better
functioning and better a prognosis. Individuals with positive symptomatology were at
higher risk for hospitalization (Fenton & McGlashan, 1991). Positive and negative
symptomatology can be measured by scales such as the PANSS (positive and negative
syndrome scale; Kay, Fiszbein, & Opler, 1987), SANS (scale for the assessment of
negative symptoms; Andreasen, 1989), and SAPS (scale for the assessment of positive
symptoms; Andreasen, 1984).
Etiology of positive and negative symptoms. Cognitive dysmetria is a theory
that seeks to explain positive and negative symptomatology in schizophrenia (Prus,
2018). Cognitive dysmetria is characterized by abnormalities with receiving and
processing information and has been linked to individuals experiencing hallucinations,
forming delusions, disorganized speech, impaired attention, and unusual responses to
emotions, all characteristic of schizophrenia (Prus, 2018). Negative symptoms of
schizophrenia have also been linked to genes in the folate metabolic pathway (Roffman et
al., 2011). Folate is an important vitamin involved in intracellular methylation, and
alteration in folate metabolism can affect normal brain development and function
(Frankenburg, 2007). Dopamine also plays a significant role in negative and positive
symptomatology in the mesolimbic pathway (Xavier & Vorderstrasse, 2017) . Abi-
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Dargham (2004) concluded that dopamine depletion in the prefrontal cortex produce
cognitive impairment and negative symptomatology.
Positive symptoms of schizophrenia have been linked to separate genes such as
MDR1 (multidrug resistance 1), with polymorphisms of this gene being associated with
hallucinations and bizarre behavior quintessential of positive symptomatology (TovillaZa’rate et al., 2014). Excessive dopaminergic action is another contribution to positive
symptoms in schizophrenia which has been a long-standing hypothesis in schizophrenia.
Anissa Abi-Dargham reported that sustained exposure to D2 receptor agonists induced
schizophrenia-like positive symptoms (Abi-Dargham, 2004). Neurotransmitters
associated with positive symptoms include dopamine and serotonin (Abi-Dargham,
2004). Abi-Dargham (2004) explains how dopamine excesses and deficits can
simultaneously produce positive and negative symptoms, respectively. He reports that
this is due to the excess of dopamine in subcortical structures such as the nucleus
accumbens and a deficit of dopamine in the cerebral cortex (Abi-Dargham, 2004). The
neurotransmitter systems producing positive and negative symptoms include dopamine,
serotonin, glutamate, and GABA. Another important neurochemical in schizophrenia is
BDNF or brain- derived neurotrophic factor (Chen et al., 2014; Xavier & Vorderstrasse,
2017), which helps maintain and form new neurons (Prus, 2018). More specifically, low
levels of plasma BDNF are related to negative symptomatology (Chen et al., 2014;
Xavier & Vorderstrasse, 2017).
Neuropsychological Function in Schizophrenia
Multiple studies have found significant deficits associated with schizophrenia in
attention, memory, processing speed, motor functioning, and executive functioning
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(Martin, Mowry, Reutens, & Robinson, 2015; Schulze-Rauschenbach et al., 2015).
Literature has found that cognitive impairment precedes the onset of the first psychotic
episode (Muntean et al., 2018).
Negative symptomatology in schizophrenia is associated with a great decline in
memory, verbal learning, nonverbal memory, verbal fluency, and processing speed
(O’Leary et al., 2000). In terms of neuropsychological testing, subjects with negative
symptomatology performed worse on IQ, Wisconsin Card Sorting Test, and The
Newcombe Word Fluency (Addington, Addington, & Maticka-Tyndale, 1991).
Positive symptomatology in schizophrenia has not shown associations with
cognitive impairment when compared to negative symptomatology. Research has shown
that cognitive impairment is far more prominent in negative symptomatology (Addington
et al., 1991) and improvement in positive symptoms is related to improvement of
cognitive functioning (Addington et al., 1991).
Executive function. Individuals with schizophrenia have difficulty with
executive function tasks such as planning, organizing, cognitive flexibility, using new
information and problem solving. Cognitive deficits in tasks that measure executive
functioning are experienced in a variety of disorders that affect prefrontal regions
(Martin, Mowry, Reutens, & Robinson, 2015).
Processing speed. Cognitive functioning depends on uniform activity between
brain regions, requiring proper speed and efficiency of information transfer which arises
from white matter microstructure (Alloza et al., 2016; Bruce et al., 2017). Processing
speed allows multiple cognitive processes to be available to the individual and is a piece
of higher order cognition (Alloza et al., 2016; Kail & Salthouse, 1994). Accelerated
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aging, which also impacts cerebral white matter, has also been linked to the
schizophrenic brain (Alloza et al., 2016).
Attention. Attention is widely dispersed among neurocognitive functions and can
encompass a wide range of tasks. This makes it difficult to isolate attention impairments
in tasks from other impairments in the same tasks (Luck & Gold, 2008). Studies have
shown different findings regarding increased and decreased activity in areas of the
schizophrenic brain and largely attribute this to the fact that attention is a multi-faceted
construct and that certain tasks can measure different areas of attention (Carter et al.,
2010).
Memory. Memory deficits seen in schizophrenia have been linked to disruptions
to the hippocampus (Zuckerman Institute, 2017). This same team completed an animal
study in which schizophrenic-like mice compared to healthy mice were studied for
memory by their ability to navigate through an environment that changed (Zuckerman
Institute, 2017). Another study indicated that pairing memory tasks with affective stimuli
may increase the ability to recall in schizophrenic patients (Fairfield et al., 2016).
Meta-Analysis
A meta-analysis is a quantitative review of the literature that combines data from
previous research studies, used to synthesize data. A meta-analysis is conducted by
forming a hypothesis and running a search on articles in databases such as PsycINFO.
Identifying articles that pertain to the hypothesis is vital and involves identifying studies
that meet the specific inclusion criteria of the study. The main statistic used in a metaanalytic review is the effect size. The effect size is a standardized measure of association
(like the correlation coefficient) or difference between groups. Effect sizes for group
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differences (like Cohen’s d or Glass’ delta) are typically computed by subtracting the
mean of the two groups and dividing by a standard deviation. After effect sizes have been
identified or calculated for each study, effect sizes are summed and averaged to compute
the grand effect size, a single metric that quantitatively summaries the research literature.
Present Study
Schizophrenia is a disabling disease that impacts the individual, the family, and
the community. Multiple factors including genetics and environment lead to
neuropsychological impairments throughout the course of schizophrenia. Clinicians have
identified symptomatologic subtypes of schizophrenia, classified as negative and
positive. Identifying the predominance of positive or negative symptom clusters can
inform the prognosis for treatment compliance, disease progression, and treatment
outcome. Research has found that individuals with schizophrenia have a marked
impairment in neuropsychological functioning when compared to healthy controls and
that progression of the disease aligns with progression of neuropsychological impairment
(Herold, Schmid, Lasser, Seidl, & Schroder, 2017). Research has also found that those
individuals with predominantly positive symptoms experience less severe
neuropsychological impairment and a better response to treatment (Addington,
Addington, & Maticka-Tyndale, 1991).
To date, research has found significant differences in neuropsychological
functioning between schizophrenia and healthy controls. However, no quantitative review
of the literature has been done. The first goal of the present study is to complete a
quantitative review of the literature that has examined neurological functioning in
schizophrenic individuals compared to a healthy control sample. It was predicted that the
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review will indicate that schizophrenia is associated with reduced executive functioning,
processing speed, attention, and memory.
Research has also indicated differences in neurological functioning between
negative and positive subtypes of schizophrenia when compared to each other. Currently,
however, there is no quantitative review of the literature looking at the relationship of
symptomatology with neurological functioning. Consequently, the second goal of the
proposed study was to conduct a meta-analytic review comparing neurological
functioning between negative and positive symptoms of schizophrenia. It was predicted
that individuals with negative symptomatology will show larger deficits in executive
functioning, processing speed, attention, and memory.
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CHAPTER II
METHOD
Neuropsychological Function: Normal Population vs Schizophrenia
A systematic search was conducted to identify studies that have compared
neurological functioning in schizophrenia and healthy control samples. The literature
search used databases such as psycINFO. The keyword combination used in the search
included combinations of the following: “IQ” (or “Intelligence”), “neurological
functioning,” “cognitive performance,” “cognition,” “neurocognitive,”
“neuropsychological,” “schizophrenia,” and “psychosis.” The studies were carefully
examined and evaluated to determine whether they fulfilled the inclusion criteria and
provided descriptive statistics and standard deviations. Additional studies were obtained
through cross-references.
Inclusion criteria consisted of the following: 1) Include studies that assessed a
sample of persons diagnosed with schizophrenia following the DSM or ICD, 2)
Comparison of schizophrenic patients with a healthy control group having no history and
familial history of psychosis, 3) Provide quantitative measures of cognitive functioning,
and 4) Be published in English in scientific peer-review journals. The effect size was
calculated by subtracting group means on cognitive measures and dividing by the pooled
standard deviation. The pooled standard deviation was calculated by adding the standard
deviations together from both groups and then dividing by two. Grand effect sizes
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involved totaling and averaging effect sizes across studies, cognitive function, and
assessment instruments.
Based on the above inclusion criteria, 19 studies were included in the metaanalysis. Overall, across these 19 studies, 861 schizophrenic patients were assessed and
858 healthy controls, who were mostly designated as community volunteers (Table 1).
Neuropsychological Function: Positive vs. Negative Schizophrenia
A second systematic search was conducted to identify studies that examined
neurological functioning across positive versus negative symptomatology in
schizophrenia. The keyword combination used in the search included the following:
“negative versus positive symptomatology,” “symptomatology in schizophrenia,” and
“neuropsychological,” “cognitive performance,” or “performance differences”. Studies
were carefully examined and evaluated to determine whether they fulfilled the inclusion
criteria and provided descriptive statistics and standard deviations. Additional studies
were obtained through cross-references.
Inclusion criteria included the following: 1) A sample of schizophrenic patients
assessed for negative and positive symptomatology, 2) Provided quantitative measures of
cognitive testing or subtests, and 3) Be published in English in scientific peer-review
journals. Effect sizes were again calculated by subtracting group means and dividing by
the pooled standard deviation.
For this second meta-analysis, 10 studies were identified that met inclusion
criteria. Across these 10 studies 1,263 patients were included in the final review (Table
4).
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CHAPTER III
RESULTS
Meta-Analysis Comparing Neuropsychological Functioning Between Schizophrenia
and Healthy Controls
It will be recalled that the purpose of the first meta-analysis was to look at the
comparison of neuropsychological functioning between schizophrenic patients and
healthy controls. Based upon the inclusion criteria, 19 studies were identified comparing
861 schizophrenic patients with 858 healthy controls. The schizophrenic sample
consisted of a fairly even split between inpatient and outpatient individuals, and most
healthy controls were community volunteers. Individual effect sizes were computed for
every neuropsychological measure and then averaged to create the grand effect sizes,
giving an estimate of the total difference between controls and the schizophrenic group.
The overall effect size for each study can be found in Table 1 along with the grand effect
size.
As can be seen in Table 1, in all instances but two, normal controls showed better
neurological functioning. In two studies, schizophrenic patients outperformed healthy
controls (Hager et al., 2015 and Krkovic et al., 2017). Overall, the grand effect size
across the 19 studies was .79. According to Cohen’s interpretation, an effect size of .79
falls in the large effect size range (Cohen, 1977). This effect size indicates that the
average person in the healthy control group outperformed 78.52% of the schizophrenic
group.i
15

In addition to calculating the overall effect size for each study, effect sizes were
also calculated for different domains of neuropsychological functioning. Table 2 presents
effect sizes for neuropsychological functioning across the following domains: Executive
functioning, attention, memory, and processing speed. The tests that were used across the
studies that assessed executive functioning included: Wisconsin Card Sorting Test, Trails
B, Digit Span total, and Stroop Word-Color. The tests that were used for processing
speed included Trails A and the Conners’ Continuous Performance Test Hit Reaction
Time. The test used for attention included the Digit Span Forward and Conners’
Continuous Performance Test detectability. The test used for memory included Digit
Span Backward.
As can be seen in Table 2, across all measures of executive functioning,
processing speed, attention, and memory, healthy controls outperformed the
schizophrenic group in all areas. The overall effect size for executive functioning was
.83. This was the same effect size for processing speed. These effect sizes represent a
large effect per Cohen, with healthy controls performing better than 79.67% of
schizophrenics in the areas of executive functioning and processing speed. The overall
effect size for attention was .51, resulting in a medium effect size per Cohen. When
broken down into percentiles, the average healthy control outperformed 69.35% of the
schizophrenic patients in measures of attention. Finally, the overall effect size of memory
was .34, which falls into the medium effect size per Cohen. The average healthy control
outperformed 63.31% of the schizophrenic patients on measures of memory.
An additional analysis computed effect sizes across assessment instruments.
These effect sizes are presented in Table 3. As can be seen in Table 3, the
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neuropsychological measures that were used consisted of Trails A, Trails B, Digit Span
Forward, Digit Span Backward, Stroop Word-Color, Wisconsin Card Sorting Test, and
The Conners’ Continuous Performance Test. Across all measurements of
neuropsychological functioning, healthy controls outperformed schizophrenics. The
lowest effect size was .30 for the Conners’ Continuous Performance Test Detectability,
and the highest effect size was 1.14 for the Stroop Word-Color Test.
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Table 1
Studies in Meta-Analysis, Population, and Overall Effect Sizes
Study:

Schizophrenia N

Healthy Controls N

d

52 outpatients

53 hospital staff

.89

30 patients

30 volunteers

.49

Ekerholm et al. 2012

36 inpatients

46 community

.80

Galaverna et al. 2012

32 inpatients

32 community

1.60

Gigaux et al. 2013

10 outpatients

10 community

1.04

Gorissen et al. 2005

64 outpatients

44 community

1.37

Hager et al. 2015

29 in and outpatient

27 community

-.06

Herold et al. 2018

80 inpatients

60 community

.71

Hughes et al. 2002

62 outpatients

25 volunteers

.67

Kalwa et al. 2012

34 outpatients

30 community

1.30

35 in and outpatient

28 community

-.44

Laurensen et al. 2015

19 outpatients

30 volunteers

1.25

Lopez-Luengo et al. 2016

89 inpatients

74 community

.71

Martino et al. 2007

21 outpatients

15 community

1.02

Matsui et al. 2007

35 inpatients

24 community

1.44

Nestor et al. 2014

48 patients

52 volunteers

.74

Perianez et al. 2007

127 inpatients

223 volunteers

.62

Sanz et al. 2012

40 inpatients

40 community

.11

Stone et al. 1998

18 males

15 male community

.70

N = 861

N = 858

Grand d = .79

Breton et al. 2011
Egan et al. 2011

Krkovic et al. 2017

Note: Positive d indicates that the healthy controls outperformed the schizophrenic
sample
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Table 2
Studies in Meta-Analysis, Neuropsychological Functioning, and Overall Effect Sizes
Study:

Executive
Functioning
.86

Attention

Egan et al. 2011

.21

.77

Ekerholm et al. 2012

.78

.80

Breton et al. 2011

Galaverna et al. 2012

Processing
Speed

.85

1.60

Gigaux et al. 2013

1.09

.93

Gorissen et al. 2005

1.37

1.38

Hager et al. 2015

.15

-.21

Herold et al. 2018

1.32

.28

.76

Hughes et al. 2002

.70

.51

.73

Kalwa et al. 2012

1.26

.38

1.41

Krkovic et al. 2017

-.98

-.71

Laurensen et al. 2015

1.13

1.50

Lopez-Luengo. 2016

.20

Martino et al. 2007

1.02

Matsui, 2007

1.44

Nestor et al. 2014

.74

Perianez et al. 2007

.63
-.28

Stone et al. 1998

.65
.83

.49

1.21

.61

Sanz et al. 2012
Grand d:

Memory

.51

19

.49
.75
.83

.34

Table 3
Studies in Meta-Analysis, Neuropsychological Tests, and Overall Effect Sizes
Study:
Breton et al. 2011

STROOP

TMT
A

TMT
B

DS
F

DS
B

1.05

Egan et al. 2011
Ekerholm et al. 2012

.85

1.02

Galaverna et al. 2012

CPT
D

.21

.77

.81

.93

1.37

Gorissen et al, 2005

1.45

1.38

1.66

Hager et al. 2015
Herold, 2018

.76

1.32

Hughes et al. 2002

.80

.82

Kalwa et al. 2012

1.41

1.58

Krkovic et al. 2017

-.71

-.98

1.50

1.03

.54

1.23

.15

-.21

.28

.49
.58

.38

.51

.66

.20

1.21

-.28

.49

.30

.79

1.60

Lopez-Luengo, 2016
Martino et al. 2007

1.02

Matsui, 2007

1.44

Nestor et al. 2014

.74

Perianez et al. 2007

.61

.63

Sanz et al. 2012
Stone et al. 1998
Grand d:

CPT
HRT

1.60

Gigaux et al. 2013

Laurensen et al. 2015

WCST
CC
.72

1.14

.84

.94

.65

.75

.75

.34

.77

Note: STROOP = Stroop Test, TMT A and B = Trail Making Test A and B, DS F and B
= Digit Span Forward and Backward, WCSTCC = Wisconsin Card Sorting Categories
Completed, CPT D and HRT = Conners’ Continuous Performance Test Detectability and
Hit Reaction Time
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Meta-Analysis Comparing Negative and Positive Symptomatology of Neurological
Functioning
A second purpose of this study was to look at the impact of positive and negative
symptomatology upon neuropsychological functioning. Literature suggests that
predominantly negative symptomatology is more associated with dysfunction than those
experiencing predominantly positive symptomatology (Sarkar, Hillner, & Velligan,
2015). Based on inclusion criteria, 10 studies were identified (Table 4). The 10 studies
were comprised of 1,263 patients diagnosed with schizophrenia and consisted of inpatient
and outpatient individuals. Most of the studies utilized the PANSS, SAPS, and SANS to
assess symptomatology.
For the studies found in Table 4, effect sizes were computed for all neurological
assessments comparing negative and positive symptomatology groups and then averaged
to create the overall effect size for that study. These effect sizes were then summed and
averaged to compute the grand effect size. As can be seen in Table 4, across all studies,
with two exception, Cascella et al. (2008) and Zakzanis (1998), predominantly positive
symptomatology schizophrenics performed better than predominantly negative. The
overall effect size was .51. The lowest effect size observed was -.95 and the highest
observed was 1.91. When interpreting the overall grand effect size of .51, Cohen defines
this as a medium effect size. Overall, this indicates that the average schizophrenic patient
with positive symptomatology performed better than 69.35% of the schizophrenics with
negative symptomatology.
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Table 4
Studies in Meta-Analysis, Population, and Overall Effect Sizes
Study

Sample

N
20

Negative/Positive
Assessment
SANS/SAPS

Bird, 1990

Outpatient

Brazo et al. 2002

.26

Outpatient

26

SDS/PANSS

.65

Cascella et al. 2008

Inpatient/Outpatient

105

SANS/SAPS

-.06

Fervaha et al. 2016

Outpatient

657

PANSS

.29

Inpatient/Outpatient

20

SAPS/SANS

.18

Mattson et al. 1997

Inpatient

40

PANSS

1.91

Murray, 1990

Inpatient

32

SANS/SAPS

.71

Polgar et al. 2010

Inpatient

275

PANSS

.77

Singh et al. 1999

Outpatient

50

SANS/SAP

1.32

Inpatient/Outpatient

38

BPRS

-.95

Jonsdottir, 1992

Zakzanis, 1998

N = 1,263

d

Grand d = .51

Note: SANS= Scale for the Assessment of Negative Symptoms SAPS= Scale for the
Assessment of Positive Symptoms PANSS= The Positive and Negative Syndrome Scale
BPRS= The Brief Psychiatric Rating Scale

As with the first meta-analysis, effect sizes were also computed for each cognitive
function. These effect sizes can be found in Table 5. The same measures went into the
same categories of neuropsychological functioning. The results were very widespread.
One negative effect size was observed with attention (d = -.12). This score indicates that
schizophrenics with negative symptomatology performed better than schizophrenics with
positive symptomatology, though this effect was small. The largest effect size was
observed for memory (d = 1.15), indicating that schizophrenics with positive
symptomatology performed on average over one standard deviation better than
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schizophrenics with negative symptomatology. The overall effect size for executive
functioning was .54, indicating that schizophrenics with positive symptomatology
performed on average a half standard deviation better than the average schizophrenic
patient with negative symptomatology. Lastly, the overall effect size for processing speed
was observed to be .25, a small effect size, indicated that the average patient with positive
symptomatology performed better than 59.99&% patients with negative
symptomatology.

Table 5
Studies in Meta-Analysis, Neuropsychological Functioning, and Overall Effect Sizes
Study
Bird,1990

Executive
Functioning
.58

Brazo et al. 2002

.65

Cascella et al. 2008

-.13

Fervaha et al. 2016

.29

Jonsdottir, 1991

.31

Mattson et al. 1997

2.66

Murray, 1990

.68

Polgar et al. 2010

.77

Singh, 1999

Attention
-.26

Processing
Speed
.59

-.95

Grand d:

.54

.66

-.03
-.24
.65

.50

.00

.40

.52

1.01

-.77

Zakzanis, 1998

Memory

3.41
-.97

-.12

.25

1.15

Effect sizes were also calculated for each cognitive assessment instrument. These
effect sizes can be found in Table 6. The measures included were the WCST, Stroop, DS,
TMT, and CPT. Across all measures, except two (DSF, CPT d’), patients with positive
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symptomatology performed better. Overall, the effect size for the Stroop was observed to
be .56, indicating that the positive symptomatology group outperformed the negative
symptomology group on this assessment by over a half standard deviation. Following
Cohen’s interpretation, this would be a medium effect size. The overall effect size for
Trails A was observed to be .22. According to Cohen (1988), this is a small effect size.
The overall effect size for Trails B was observed to be .87, a large effect. The overall
effect size for Digit Span Forward (DSF) was observed to be -.16, indicating that positive
symptomatology group performed worse than negative symptomology group on this
measure of attention. The effect size for Digit Span Backward was 1.15, a large effect.
The overall effect size for Wisconsin Card Sorting Test was .29, a medium effect
indicating that the average participant with positive symptomatology performed better
than 61.41% of those in the negative symptomatology group. The effect size for the
Conners’ Continuous Performance Test Detectability was observed to be negative (d = .14), indicating that those in the negative symptomatology group performed better on the
CPT d’ than the positive symptomatology group. The overall effect size for Continuous
Performance Test Hit Reaction Time was .18, which is a small effect size per Cohen.
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Table 6
Studies in Meta-Analysis, Neuropsychological Testing, and Overall Effect Sizes
Study:

STROOP

Bird, 1990
Brazo et al. 2002

TMT
A
.59

TMT
B
.58

DSF

DSB

-.24

.66

.56

Cascella et al. 2008

CPT
D
-.28

CPT
HRT

.00

.18

-.14

.18

.73
-.23

-.16

-.10

Fervaha et al. 2016

.29

Jonsdottir, 1991

.50

.43

Mattson et al. 1997

.40

4.77

Murray, 1990

1.01

.70

-.24

.00

.19
.55

.65

.52

Polgar et al. 2010

.65
.77

Singh, 1999

-.77

Zakzanis, 1998
Grand d:

WCST
CC

.56

-.97

-1.11

.22

.87

3.41
-.78

-.16

1.15

.29

Note: STROOP = Stroop Test, TMT A= Trail Making Test A, TMT B= Trail Making
Test B, DSF= Digit Span Forward, DSB= Digit Span Backward, WCSTCC= Wisconsin
Card Sort; Categories Completed, CPD D = Conners’ Performance Test Detectability,
CPT HRT= Conners’ Performance Test Hit Reaction Time

Meta-Analysis Comparing Error Rates Between Schizophrenic Patients and
Healthy Controls
A final, exploratory analysis was made of the error rates during the
neurocognitive testing of schizophrenic patients and healthy controls. Using the studies
from Table 1, nine studies were identified that provided error rates for the Wisconsin
Card Sorting Test and the Conners’ Continuous Performance Test. Effect sizes were
calculated for Wisconsin Card Sorting Test for the errors made in perseverations, or
repeating the prior rule despite clinician instructions. In addition, effect sizes were also
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computed for the number of incorrect responses on the Wisconsin Card Sorting Test that
did not involve perseverations. Effect sizes were also calculated for omission errors on
the CPT, the number of missed targets. Such errors indicate an individual was not
responding to target stimuli, due to factors such as inattentiveness or a difficulty with
focusing. Effect sizes were also calculated for commission errors on the CPT, which are
incorrect responses to non-targets -- errors that can indicate inattention or impulsivity.
Effect sizes for errors on cognitive tests between schizophrenic patients and
normal controls are found in Table 7. Positive effect sizes indicate that healthy controls
performed better (fewer errors) than schizophrenic patients. Across the studies, all effect
sizes, except one, were positive, indicating that healthy controls had fewer errors.

Table 7
Studies Comparing Schizophrenics with Non-Patients, Errors and Overall Effect Sizes.
Study

WCST PE

WCST NONPE

Breton et al. 2011

.89

.61

Egan et al. 2011

.30

-.05

Ekerholm et al. 2012

.72

Hughes et al. 2002

.36

Kalwa et al. 2012

1.34
1.05

Nestor et al. 2014

.76

.69

.31

.93

.32

1.20

.61

.94

.41

.30

Sanz et al. 2012
Grand d:

CPT COM

1.93

Lopez-Luengo, 2016
Martino et al. 2007

CPT OM

.77

.70

Note: WCSTPE: Wisconsin Card Sorting, Perseverative Errors; WCSTNON, Wisconsin
Card Sorting, Non-Perseverative Errors; CPTOM, Conners’ Continuous Performance
Test, Omissions; CPTCOM, Conners’ Continuous Performance Test, Commissions
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CHAPTER IV
DISCUSSION
Schizophrenia effects more than 21 million people worldwide (World Health
Organization, 2019) and continues to elude clinicians and researchers for a cure.
Schizophrenia can be considered a brain disease with a chronic course and stable
neurocognitive deficits (National Institute of Mental Health, 2016). Studies over the years
have examined the relationship between schizophrenia and healthy controls on
neurological functioning, and the goal of this meta-analysis was to contribute to that
literature. Overall, 19 studies were identified that met inclusion criteria comparing a
schizophrenic sample and healthy controls on some measure of neurological functioning.
Across these studies, a total of 861 schizophrenia patients and 858 healthy controls were
included. The overall effect size was .79, indicating that the average healthy control
performed better than 78.52% of the schizophrenic patients. When broken down by
neurological function, the greatest deficits were observed in the areas of processing speed
and executive functioning. Overall, the meta-analysis was consistent with the findings
that there are persistent neurological deficits associated with schizophrenia.
The second goal of the study was to conduct a meta-analysis looking at positive
and negative symptomatology and neuropsychological functioning. For generations,
clinicians and researchers have noted the complex presentation of schizophrenia
symptoms. Schizophrenic patients presenting with negative symptoms display symptoms
such as: blunt/flat affect, anhedonia, alogia, and avolition (National Institute of Mental
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Health, 2016). Positive symptoms, by contrast, involve hallucinations and delusions
(National Institute of Mental Health, 2016). Clinicians and researchers have noted a more
disabling course for the disorder when negative symptoms are the primary presentation
(Rabinowitz, 2012). Thus, a goal of this study was to look at the cognitive functioning of
positive and negative schizophrenia. Based upon the inclusion criteria, 10 studies were
identified involving 1,263 patients. Overall, the effect size between the symptom types
calculated to .51, indicating that positive symptomatology performed better than 69.35%
of the schizophrenics with primary negative symptoms with the most profound
neuropsychological functioning deficit being memory.
Implications
Clinical Implications
From the time of diagnosis, the course of schizophrenia has deleterious effects on
the individual, the family, and the community (Miller, 1996). Managing symptoms within
the day-to-day function can be very difficult for those struggling with disease. When
considering treatment of schizophrenia, it is in the best interest of the individual to have
family support. Family therapy may be of benefit to both the patient and the support
system (Dixon & Lehman, 1995; Jewell, Downing, & McFarlane, 2009). In light of the
current review, beyond the need for psychopharmacological intervention cognitive
remediation and other forms of skills-based therapies may be helpful for the individual
(Lopez-Luengo et al., 2016; Sanz et al., 2012). Many researchers have noticed a better
outcome and improved cognitive functioning with early diagnosis and intervention, such
as psychopharmacology, cognitive remediation, psychotherapy, occupational therapy,
and ongoing case management services (Herold et al., 2019; Hughes et al., 2003).
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Treatment compliance has been a long-standing concern and challenge for some
individuals with schizophrenia (Fenton et al., 1997). Mental illness stigma, insight,
substance use, medication side effects and lack of support, for example, can contribute to
treatment non-compliance for those struggling with the diagnosis (Fenton et al., 1997).
This can also raise clinical implications for neurocognitive functioning and treatment
noncompliance. Cognitive functioning should be considered as early as diagnosis, and the
discussion of selecting a caretaker or adult protective agency to assist when symptoms
may impair adequate treatment could be a viable resource to treatment planning and
compliance.
Currently, the Diagnostic and Statistical Manual of Mental Disorder (DSM), 5th
edition (American Psychiatric Association, 2013) places cognitive impairment related to
schizophrenia in the ‘Associated Features’ section, and states that cognitive impairment is
linked to vocational or functional impairment (American Psychological Association,
2013). In light of the current review, it may be beneficial to add the cognitive criteria to
the diagnostic section in the DSM. In addition, based upon the present research, these
cognitive criteria should be evaluated quantitatively (e.g., neuropsychological tests)
rather than qualitatively (i.e., clinical impression).
Lastly, antipsychotic medication should be considered. A majority of
schizophrenic patients are prescribed second generation medications, with some
individuals requiring first-generation medications (treatment resistance schizophrenia;
TRS). It is important to understand the role that antipsychotics may have on cognitive
deficits and if the side effects may worsen the deficits. Literature indicates that cognitive
deficits are present in drug-naïve schizophrenic patients (Fatourous-Bergman et al., 2014;
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Zhang et al., 2013), indicating that cognitive deficits are present in early stages of
schizophrenia and continue with the progression of the disease.
Further, treatment of negative symptomatology can be more difficult for
clinicians compared to positive symptoms (Ellenbroek & Cools, 2000; Sarkar, Hillner, &
Velligan, 2015). Sensory gating deficits in schizophrenia expressed as difficulty tuning
out irrelevant stimuli thus posing a challenge to maintaining attention (Freedman et al.,
1987; Judd et al., 1992; Lijffijt et al., 2009). Nicotine improves sensory gating in
schizophrenia, and schizophrenic patients are at high-risk for smoking (Featherstone &
Siegel, 2015). Examining the role of nicotine and the improvement of sensory gating
could lead to treatments for improving cognitive functions without creating additional
problems with the medication effects (Hoffer et al., 1957; Levin & Rezvani, 2002).
Specifically, some medications have interactive effects when used with nicotine,
however, studies have shown that smoking can alleviate some side effects of antipsychotics (Matthews, Wilson, & Mitchell, 2011). The impact, however, is that smoking
impacts the metabolism of medications (Lyon, 1999; Ziedonis et al., 2006).
Neuropsychological Implications
Neuropsychological advancements have had a great impact on uncovering the
cognitive abilities of individuals across a variety of diagnoses. The biggest implication of
the neuropsychological assessment’s role when testing cognitive functioning for specific
diagnoses is the wide range of testing available and the need for a standardized
measurement that allows for more concise data and interpretation. During the course of
the study, it was difficult to pool data on several studies due to varying scores,
procedures, and modifications being used. Studies ranged in interpretation procedures
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with some studies using the scores set forth by the manuals and others using alternative
scoring.
Neuropsychological testing provides substantial information for research in the
schizophrenic population, and pairing this data with neuroimaging can improve the data
being used for treatment and research. These findings could assist with determining the
prognosis at a more discrete level, potentially from the prodromal phase throughout the
duration of the disease. Literature supports that cognitive functioning may be useful as a
vulnerability marker (Cornblatt, 2002; Davidson et al., 1999; Reichenberg, 2010). This
proves the need for continued research on neuropsychological measures and
schizophrenia from the early stages (prodromal) and into the depths of the disease, into
the lifespan.
Conclusion
In conclusion, this study gives evidence that schizophrenic patients experience
distinct and significant cognitive decline. In addition, negative symptomatology was
associated with greater cognitive impairment. Consequently, the assessment of positive,
negative, and cognitive symptoms when diagnosing and treating schizophrenia must
become routine in clinical practice. Regarding treatment recommendations based upon
these findings, the implementation of skill-oriented therapies along with family
involvement may lead to more successful treatments.
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